The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it’s set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.
The asset management giant reports that 11% of the global eligible population of 1.3 billion people are taking weight-loss drugs, including 20% of eligible patients in the U.S. and 10% in other countries. Morgan Stanley cites expanded supply and clinical benefits for other diseases, such as heart and kidney disease, as well as the burgeoning employer drug coverage, as primary reasons the market has taken flight.
